GlassScriptPhysician profile
Laura E Starrh
NPI 1528574993
$1,067.80
in general payments reported to CMS, 2019-2025
8 companies · $489 in 2025
The $489 reported for 2025 was more than what 76% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $246 · 2024: $333 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $244.76 | 2023-2025 | Tezspire, Andexxa |
| Teva Pharmaceuticals USA, INC. | $132.44 | 2025 | Ajovy |
| Mayne Pharma Commercial LLC | $123.83 | 2023 | |
| Averitas Pharma INC. | $121.82 | 2024 | Qutenza |
| Alk-Abello, INC | $118.98 | 2025 | |
| Alkermes, INC. | $114.39 | 2025 | Vivitrol |
| Sage Therapeutics, LLC | $106.67 | 2024 | |
| Hologic Sales and Service, LLC | $104.91 | 2024 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Starrh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.